In-hospital Falls and Hemorrhagic Complications : a Descriptive Analysis in Rennes University Hospital (HEMO-CIH)
Anticoagulant and antiplatelet treatments have well defined indactions, with a clearly proved benefit, respectivly for prevention of arterial and venous emblism and for prevention of athermo-related arterial thrombosis.
Bleeding risk represents the main adverse effect of these antithrombotic medications. Then benefit-risk ratio is sometimes difficult to evaluate, especially for elderly patients prone to fall (incidence of falls estimated to 30% per year for patients over 65), exposed on the one hand to thromboembolic risk and on the other hand to bleeding risk.
Associations between falls and antithrombotic-related bleeding risk had already been evaluated in several studies :
- Concerning anticoagulant treatments in patients at high risk of falls, retrospective studies shown a overrated risk of intracranial hemorrhage and mortality, but those results remain discordant wtih 3 major prospective studies on larger populations.
- Concerning antiplatelet treatments in patients at high risk of falls, majority of retrospective studies reported an overrated risk of major bleeding, intracranial bleeding and mortality, but datas remain fewer than for anticoagulant and results are as well discordant with prospective studies.
- No difference of morbi-mortality is clearly estalblished depending of antithrombotic treatment class (anticoagulant versus antiplatelet), however there is a cumulative risk in case of association of both anticoagulant and antiplatelet.
- Main factors associated with fall-related bleeding for patients on anticoagulant include age, female sex, anemia, chronic kidney disease, dementia and polymedication.
Thus, the purpose of this study is to specify whether occurrence of falls justify to reconsider prescription of antithrombotic treatments in patients having an indication of antiplatelet or anticoagulant therapy.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Retrospective, descriptive and non-interventional study over a period of 12 months (from 01/01/2017 to 31/12/2017), from unwanted events database of Rennes University Hospital.
Patients meeting criterias receive an information mail. Without opposition over a period of 3 weeks, datas will be treated, focusing on the event and its consequencies until hospital outing.
Baseline characteristics :
- Demographic datas : age, sex
- Antithrombotic treatement, treatment class and molecule
- Last INR dosage before the fall for patients of vitamin K antagonists
- Antithrombotic treatment indication : supra-ventricular arythmia, heart valve mecanical prothesis, severe left ventricle hypokinesia, venous thromboembolism, anti-phospholipid syndrome, myeloproliferative disorder, atheroma (in primary or secondary prevention)
- Comorbidities : history of bleeding (including hemorrhagic stroke), haemostasis disorder, thrombocytopenia, anemia, chronic kidney disease, chronic liver disease, alcohol abuse, ischemic stroke or transient ischemic stroke, cognitive disoreder, active neoplasm, HAS-BLED score, HEMORRHAGE score
- Other undergoing treatments : total number of medications, antihypertensive treatment, psychotropic treatment, non-steroid anti-inflamatory treatment
Description of fall-related bleeding events rate (until hospital outing) according to the severity :
- Any severity bleedings
- Major bleedings (hemorrhagic shock, deglobulisation, red blood cells transfusion required, vital or functional-threatening bleeding spot, uncontrolled hemorrhage requiring specialized haemostatic intervention)
- Intracranial bleeding
- Fatal bleeding
Modification of the antithrombotic prescription in the aftermath of the fall :
- Discontinuation or suspension of antithrombotic treatment
Sub-group analysis for each previous item, according to undergoing antithrombotic treatment at the moment of the fall :
- Curative-dose anticoagulant in monotherapy
- Preventive-dose anticoagulant in monotherapy
- Antiplatelet in monotherapy
- Curative-dose anticoagulant and antiplatelet in association
- Preventive-dose anticoagulant and antiplatelet in association
- No antithrombotic treatement
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Rennes, Frankrike, 35
- Centre Hospitalier Universitaire de Rennes
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Hospitalized patients in internal medicine unit in Rennes University Hospital, from 1/01/2017 to 31/12/2017
- Age over 18
- In-hospital fall reported in unwanted event database
- Separated inclusion for each fall in the same patient
Exclusion Criteria:
- Adults on legal protection (safeguarding justice, trusteeship, guardianship) or deprived of liberty
- Patient opposed to inculsion
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Any-severity fall-related hemorrhagic events rate
Tidsramme: The inclusion day
|
All reported hemorrhagic events after a fall
|
The inclusion day
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Patrick Jego, MD PhD, Rennes University Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- 35RC18_3089_HEMO-CIH
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på In-hospital Falls
-
Mespere Lifesciences Inc.FullførtPasienter henvist til St. Michael's Hospital ekkokardiografilaboratoriumCanada
-
Massachusetts General HospitalCrico; Inspiren Inc; RGI Informatics LLCHar ikke rekruttert ennåFall og fall med skade
-
Weill Medical College of Cornell UniversityFullførtModerat syke medisinske innlagte pasienter ved Cornell Campus ved New York-Presbyterian HospitalForente stater
-
University Hospital, Basel, SwitzerlandFullførtTilfeldig fall | Underliggende sykdom ved fallSveits, Tyskland
-
Shirley HuangJintronixRekruttering
-
Sigma Theta Tau InternationalRekruttering
-
CUSH Health Ltd.University of SussexHar ikke rekruttert ennåUtilsiktet fall
-
University of Maryland, BaltimoreVA Maryland Health Care SystemRekruttering
-
National Opinion Research CenterCenters for Disease Control and Prevention; Emory HealthcareFullført
-
Virginia Polytechnic Institute and State UniversityFullført